The UK and US have hammered out a key bilateral deal that will guarantee no import taxes on British pharmaceutical exports going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on drugs through the NHS. This pledge secures that duties on these vital exports will be held at nothing for a duration of three years.
This deal is in response to earlier statements to hike tariffs on patented pharmaceutical imports, with increases floated reaching one hundred percent.
"This agreement with the UK reinforces the global environment for new treatments and introduces much-needed fairness to transatlantic drug exports," a statement declared.
Commercial Significance
Pharmaceuticals are one of the UK's biggest goods shipped to the United States, which is easily the primary buyer for leading British pharmaceutical firms.
Export figures indicate that in the 12 months prior to last September, the UK shipped drugs worth over eleven billion pounds to the US. This amount made up 17.4% of total UK exports in that span.
"This agreement safeguards jobs, stimulates funding and sets the stage for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to double overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must refund to the NHS to control costs will be restricted at 15%. Previously, repayments exceeded twenty percent.
Recent Tensions
The deal comes amid a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were intensified by arguments that US consumers were charged significantly more for the equivalent treatments than people in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward American operations.
A senior figure stated that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the past decade.